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Abstract Here we review the current understanding of the
genetic architecture of intracranial berry aneurysms (IBA) to
aid in the genetic counseling of patients at risk for this condi-
tion. The familial subtype of IBA, familial intracranial aneu-
rysms (FIA), is associated with increased frequency of IBA,
increased risk of rupture, and increased morbidity and mortal-
ity after rupture. Family history is the strongest predictor for
the development of IBA. However, a genetic test is not yet
available to assess risk within a family. Studies using linkage
analysis, genome-wide association, and next-generation se-
quencing have found several candidate loci and genes associ-
ated with disease onset, but have not conclusively implicated a
single gene. In addition to family history, a separate or con-
current diagnosis of autosomal dominant polycystic kidney
disease is a strong genetic risk factor for IBA formation. We
also discuss the relative risk for developing IBA in several
Mendelian syndromes including vascular Ehlers-Danlos syn-
drome, Marfan syndrome, Neurofibromatosis Type I, and
Loeys–Dietz syndrome.
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aneurysms . Linkage analysis . Genome-wide association
study .Whole-exome sequencing . Autosomal dominant
polycystic kidney disease . Ehlers-Danlos syndrome .Marfan
syndrome . Neurofibromatosis type I . Loeys-Dietz syndrome
Introduction
Intracranial berry aneurysms (IBA) develop in the walls of
cerebral arteries where the endothelial layer has weakened
and formed a sac-like abnormality. IBA are also referred to
as saccular aneurysms and differ from other intracranial aneu-
rysms in shape, forming an out-pocketing off of a cerebral
artery, reminiscent of a berry on a vine. Fusiform aneurysms
involve dilatation of the entire vessel wall for some compo-
nent of its length; in the cerebral circulation they are much
rarer that berry aneurysms (Park et al. 2008). It is estimated
that 3 % of the general population have at least one IBA
(Rinkel et al. 1998; Vlak et al. 2011), a prevalence that in-
creases to 3.6–6.5 % in people over 30 years of age (Krischek
and Inoue 2006). Aneurysmal rupture accounts for a signifi-
cant proportion (80–85 %) of subarachnoid hemorrhage
(SAH) (Brown and Broderick 2014). SAH is fatal in 35–
50 % of patients, and leads to permanent brain damage in
25–50 % of survivors (Rinkel and Algra 2011; Ronkainen
et al. 1998; Rosenorn et al. 1987; Schievink 1997).
Population-wide screening is not currently recommended, as
most cerebral aneurysms are asymptomatic and will never
rupture (Ronkainen et al. 1998). From a genetic epidemiology
perspective, IBA are considered to be a common, complex
condition with multiple risk factors including advanced age,
ancestry, sex (women affected more often than men),
smoking, longstanding hypertension, and family history
(Brown et al. 2008; The International Study of Unruptured
Intracranial Aneurysms Investigators 1998; Juvela et al.
2001; Leblanc 1996). Familial intracranial aneurysms (FIA),
a hereditary subtype of IBA, is suspected when two or more
affected first- to third- degree relatives are present in a family
(Fig. 1a and b) (Bederson et al. 2000). Differences in study
populations and methodology have contributed to variability
in the reported prevalence of FIA. For example, the rate of
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detection of intracranial aneurysms when screening first-
degree relatives with at least two affected family members
has been reported to be 9.2–9.8 % in patients older than
30 years, which is approximately 2–3 times higher than the
risk within the general population (Ronkainen et al. 1998;
1997). A more recent study screened for aneurysms among
asymptomatic first-degree relatives of families with two af-
fected first-degree relatives or three affected second- to
third- degree relatives, and found detection rates as high as
20.6 % among patients older than 30 years (Broderick et al.
2009). Individuals with FIA seem to have a more severe phe-
notype: they are more likely to develop more than one brain
aneurysm (Brown and Broderick 2014; Rinkel et al. 1998),
and have 17 times greater risk of rupture compared to those
with sporadic IBA (Broderick et al. 2009). Furthermore, an-
eurysms that do rupture tend to rupture at a younger age and at
a smaller diameter among patients with FIA (Bacigaluppi
et al. 2013; Broderick et al. 2009; Lozano and Leblanc
1987). Along with the increased risk for aneurysm formation
and rupture, patients with FIA appear to have a poorer out-
come after rupture (Bromberg et al. 1995; Kojima et al. 1998).
Generally, screening with magnetic resonance angiography
(MRA) or computerized tomographic angiography (CTA) is
recommended for individuals with two or more first-degree
relatives diagnosed with intracranial aneurysms (Bor et al.
2010, 2014; Brisman et al. 2006; Brown et al. 2008;
Ronkainen et al. 1998; Thompson et al. 2015). In the absence
of prospective longitudinal studies, expert consensus appears
to be that relatives at sufficient risk to merit screening should
begin such screening 10 years prior to the earliest age-at-
diagnosis in their pedigree.
For the benefit of genetic counselors, who may be consulted
by patients concerned about their risk for intracranial aneu-
rysms, or who may discover a family history of intracranial
aneurysms during a routine session, we present here a review
of the genetics of IBA, and of the knownMendelian syndromes
that confer increased risk for IBA. For a review of the natural
history of IBA and options for treatment, we refer interested
readers to the American Heart Association/American Stroke
Association 2015 Guidelines (Thompson et al. 2015) and to a
recent review article by Brown and Broderick (2014).
Family Mapping Studies
Familial mapping studies have been done in large pedigrees that
appear to have a single genetic variant as a major risk factor for




Fig. 1 Pedigrees of three families
diagnosed with familial
intracranial aneurysms suggesting
dominant inheritance (a), and
inheritance consistent with
dominant or X-linked
transmission (b). Part (c) shows a
sporadic case of an intracranial
berry aneurysm; its onset in
childhood in the absence of
known environmental risk factors
is consistent with a major genetic
risk factor such as a de novo
pathogenic variant
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hypothesis that such a variant will be found in a chromosomal
region that has been commonly inherited by all affected family
members. Markers of known genomic location, such as single
nucleotide polymorphisms (SNPs), are used to derive haplo-
types that can in turn be used to identify loci that co-segregate
with FIA. Investigations of families and affected sibling-pairs
have suggested numerous loci associated with FIA (Table 1).
From these studies the loci with the strongest association are
7q11, 19q13, and Xp22. (Farnham et al. 2004; Foroud et al.
2008, 2009; Kim et al. 2011; Mineharu et al. 2007; Nahed et al.
2005; Olson et al. 2002; Onda et al. 2001; Ozturk et al. 2006;
Roos et al. 2004; Ruigrok et al. 2008; Santiago-Sim et al. 2009;
van der Voet et al. 2004; Verlaan et al. 2006; Yamada et al.
2004). A recent meta-analysis of five familial mapping studies
revealed an additional two loci in linkage disequilibrium with
FIA, 3q27.3-3qter and 17p12-q21.33 (Biros and Golledge
2008). A SNP association study aimed at replicating loci pre-
viously flagged by linkage analysis confirmed the association at
14q23 (found by (Ozturk et al. 2006)) in a cohort of 266
affected and 288 unaffected Japanese individuals (Mineharu
et al. 2008). The number of loci identified though linkage anal-
ysis indicates there is genetic heterogeneity in FIA.
Genome-Wide Association Studies
Genome-wide association studies (GWAS) interrogate the ge-
nome for statistically significant associations between SNPs
and disease at a population level. Several loci have been as-
sociated with sporadic IBA by GWAS, primarily using large
discovery and replication cohorts from the Dutch, Finnish,
and Japanese populations (Table 2) (Abrantes et al. 2015;
Bilguvar et al. 2008; Deka et al. 2010; Foroud et al. 2012,
2014; Kurki et al. 2014; Low et al. 2012; Yasuno et al.
2011, 2010). The most frequently replicated locus is 9p21.3,
which contains the long non-coding RNA, CDKN2B–AS1,
and is adjacent to the cyclin-dependent kinase inhibitor genes,
CDKN2A and CDKN2B. The same linkage block in 9p21.3
Table 1 Loci associated with familial intracranial aneurysms by linkage analysis











1p36.13-p34.3 North American, Dutch ANIB3 609,122 Yes 12(8) from 1 family
7(10) from 1 family
Nahed et al. (2005)
Ruigrok et al. (2008)
2p13 Dutch - - No 7(9) from 1 familya Roos et al. (2004)
4q32.2 FIA Study - - Yes 192 familiesb,c
333 familiesb,c
Foroud et al. (2008)
Foroud et al. (2009)
5p15.2-p14.3 French-Canadian ANIB4 610,213 No 9(3) from 1 family Verlaan et al. (2006)
5q22–33 Japanese - - No 104 ASP from 85 families Onda et al. (2001)
7q11.2 Japanese, North American ANIB1 105,800 Yes 104 ASP from 85 families
39(0) from 13 families
Onda et al. (2001)
Farnham et al. (2004)
8p22 South Korean ANIB11 614,252 No 9(22) from 5 families Kim et al. (2011)
11q24-q25 Colombian, North American ANIB7 612,161 Yes 2 familiesb Osturk et al. (2006)
12p12.3 FIA Study - - Yes 333 families Foroud et al. (2009)
13q14.12-q21.1 French-Canadian - - No 10(25) from 1 family Santiago-Sim et al. (2009)
14q22 Japanese - - No 104 ASP from 85 families Onda et al. (2001)
14q23 Colombian, North American ANIB8 612,162 Yes 2 familiesb Ozturk et al. (2006)
17cen Japanese - - No 93(27) from 29 families Yamada et al. (2004)
19q13 Finnish, Japanese ANIB2 608,542 Yes 48 ASP from 22 families
222 ARP from 121 families
93(27) from 29 families
41(0) from 9 families
Olson et al. (2002)
van der Voet et al. (2004)
Yamada et al. (2004)
Mineharu et al. (2007)
Xp22 North American, Japanese, Dutch ANIB5 330,870 Yes 48 ASP from 22 families
93(27) from 29 families
7(10) from 1 family
Olson et al. (2002)
Yamada et al. (2004)
Ruigrok et al. (2008)
Study cohort data corresponds with the reference in each horizontal row. ASPAffected sib-pair; ARPAffected relative pair
a Family is consanguineous
b The number of affected and unaffected individuals included in the linkage analysis was not available
c A total of 1155 affected and 1895 unaffected familymembers were genotyped in Foroud et al. (2008) and Foroud et al. (2009). Families were enrolled at
recruitment sites located in North America, New Zealand, and Australia
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associated with IBA has also been associated with other vas-
cular diseases, including coronary artery disease, myocardial
infarction, and abdominal aortic aneurysms: this suggests that
there may be a single locus that predisposes to all of these
conditions via a common pathology (Helgadottir et al. 2008,
2007). Alg et al. (2013) conducted a meta-analysis of 61
GWAS studies that replicated the association between three
loci (9p21.3, 8q11, and 4q31.23) and IBA. In contrast to the
postulated high-penetrance Mendelian loci in FIA, loci
discerned through GWAS each have a relatively small effect
size on the risk of developing IBA. For example, SNPs at the
strongest associated locus, 9p21.3, have reported odds ratios
between 1.29–1.34 in the major GWAS studies (Bilguvar et al.
2008; Foroud et al. 2014; Yasuno et al. 2010).
Next-Generation Sequencing Studies
Unlike GWAS, but similar to linkage analysis, whole-exome
sequencing (WES) aims to identify rare variants that have a large
effect size and impart a high risk of developing intracranial an-
eurysms. Recently, three WES studies of multiplex families di-
agnosed with FIA have revealed new candidate genes in the
development of intracranial aneurysms. All three studies
excluded individuals who were diagnosed with a syndromic
form of IBA.
The Familial Intracranial Aneurysm (FIA) Study published
two exome sequencing studies on seven multiplex families of
European-American ancestry. These families were selected for
having high numbers of affected individuals, and for having
pedigrees consistent with either autosomal dominant or autoso-
mal recessive inheritance. Initially, WES was carried out on 50
affected and unaffected individuals from these families, and anal-
ysis identified 96 candidate genes (Foroud for the FIA Study
Investigators 2013). In their second publication (Farlow et al.
2015), the FIA Study researchers analyzed WES data from 36
affected and 9 unaffected family members. Unaffected family
members were only included if they were above 45 years of
age and had received a negative screen by MRA. It is of course
possible that some of the family members who were scored as
unaffected may yet develop an IBA in their lifetime. For this
analysis, Farlow et al. (2015) employed six biological filters on
their WES data to generate a list of 68 candidate variants in 68
genes. These filters examined the variant type (non-synonymous
SNVs or exonic and splice site indels), variants with a minor
allele frequency (MAF) of <0.01, the segregationwithin families,
and the predicted effect on protein (via CADD score ≥ 10, and
predicted damaging by Polyphen2 or SIFT). Five variants, found
Table 2 Loci associated with intracranial berry aneurysms through genome-wide association studies
Associated
Loci




Replicated in > 1
population
Size(s) of Study Cohort References
2q33.1 Dutch, Finnish, Japanese ANIB9 612,586 Yes 2196 cases; 8085 controls Bilguvar et al. (2008)
4q31.22 Japanese - - No 2431 cases; 12,696 controls Low et al. (2012)
4q31.23 Dutch, Finnish, Japanese - - Yes 5891 cases; 14,181 controls Yasuno et al. (2010)
Yasuno et al. (2011)
5q31.3 Finnish, Dutch - - Yes 2335 cases; 9565 controls Kurki et al. (2014)
8q11.12–12.1 Dutch, Finnish Japanese ANIB10 612,587 Yes 2196 cases; 8085 controls
5891 cases; 14,181 controls
406 cases; 392 controls
1483 cases; 1683 controls
Bilguvar et al. (2008)
Yasuno et al. (2010)
Deka et al. (2010)
Foroud et al. (2012)
8q21.3 Dutch, Finnish, Japanese - - Yes 5891 cases; 14,181 controls Yasuno et al. (2010)
9p21.3 Dutch, Finnish,
Japanese, Portuguese
ANIB6 611,892 Yes 2196 cases; 8085 controls
5891 cases; 14,181 controls
406 cases; 392 controls
1483 cases; 1683 controls
4133 cases; 7869 controls
2431 cases; 12,696 controls
200 cases; 499 controls
Bilguvar et al. (2008)
Yasuno et al. (2010)
Deka et al. (2010)
Foroud et al. (2012)
Foroud et al. (2014)
Low et al. (2012)
Abrantes et al. (2015)
10q24.32 Dutch, Finnish, Japanese - - Yes 5891 cases; 14,181 controls Yasuno et al. (2010)
12q22 Dutch, Finnish Japanese - - Yes 5891 cases; 14,181 controls Yasuno et al. (2011)
13q13.1 Dutch, Finnish Japanese - - Yes 5891 cases; 14,181 controls Yasuno et al. (2010)
18q11.2 Dutch, Finnish, Japanese - - Yes 5891 cases; 14,181 controls Yasuno et al. (2010)
20p12.1 Dutch, Finnish, Japanese - - Yes 5891 cases; 14,181 controls Yasuno et al. (2011)
The size of each study cohort corresponds with the reference in the same horizontal row. Yasuno et al. (2010) and Yasuno et al. (2011) analyzed the same
discovery and replication cohorts, which were expanded on from the cohort studied in Bilguvar et al. (2008)
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inGSTCD,DUSP16, LMBR1L,HAL andTSC2, segregated fully
with disease in one family and were present in the affected indi-
viduals of a second FIA family. None of the variants found in this
study overlapped with any GWAS flagged loci (Farlow et al.
2015). This is presumably because rare, highly-penetrant patho-
genic variants that result in a Mendelian inheritance pattern in a
multiplex family tend not to spread through to the general pop-
ulation (unless some sort of balancing selection occurs).
Yan et al. (2015) had broader inclusion criteria and sequenced
families with three or more affected first- to third- degree rela-
tives. They sequenced 42 affected people from 12 families of
Japanese ancestry. After filtering for their presence in all affected
family members, minor allele frequency (MAF) <0.05, and a
predicted damaging effect to the protein (Polyphen2 and SIFT),
WES analysis resulted in 78 candidate variants. Two variants,
p.Y193F inGPR63 and p.R142H in C10orf122 (TEX36), segre-
gated with affected individuals in more than one family. While
both of these protein changes are predicted to be deleterious,
relatively little is known about the gene function and there was
not sufficient evidence to classify either mutation as pathogenic.
Yan et al. (2015) then selected ten variants from nine genes,
based on functions that were plausibly associated to the patho-
genesis of intracranial aneurysms, for Sanger sequencing and
replication in two additional Japanese cohorts. The first replica-
tion cohort consisted of probands from 24 independent FIA fam-
ilies, and the second replication cohort included 426 individuals
diagnosed with sporadic IBA. Avariant in ADAMTS15 was sig-
nificantly associated with the familial cases in the first replication
cohort, while variants in THBD, IL11RA, PAFAH2, and ZNF222
had a slightly increased MAF among the sporadic IBA cases in
the second replication cohort compared to the Japanese
population.
For rare diseases with characteristic phenotypes, a gene-
disease association is established when rare variants are present
in the same gene in three independent families. For more com-
mon diseases such as IBA, issues such as non-penetrance and
phenocopies make additional evidence (such as functional stud-
ies) highly desirable in order to lower the false discovery rate.
Whereas none of the candidate genes yet flagged through these
WES studies have sufficient genetic evidence to prove a causal
association, genes containing variants that co-segregate with dis-
ease in multiplex families are the best candidates to date, and
may be implicated (or discarded) by future next-generation se-
quencing studies.
Syndromes Conferring Susceptibility to IBA
Autosomal Dominant Polycystic Kidney Disease
Apart from family history, diagnosis of autosomal dominant
polycystic kidney disease (ADPKD) imparts the highest risk
for developing IBA (Table 3). Between 4 % and 17 % of
patients with ADPKD will develop IBA, with an equal risk
distribution between genders (Chapman et al. 1992; Huston
et al. 1993; Niemczyk et al. 2013; Ruggieri et al. 1994; Xu
et al. 2010). As seen with non-syndromic IBA, the prevalence
of IBA increases with age in this disease (Niemczyk et al.
2013; Xu et al. 2010). The combined risk for aneurysmal
formation in patients diagnosed with ADPKD and a family
history of IBA or SAH increases to approximately 22–25 %
(Huston et al. 1993; Ruggieri et al. 1994). Screening for IBA
in ADPKD is recommended in patients above 30 years of age,
or in patients with a family history of IBA (Xu et al. 2010).
Hypertension, found commonly in ADPKD patients, is not
considered to be an obligatory risk factor for aneurysm forma-
tion in this context. Individuals with ADPKD who have well-
controlled hypertension, or hypertension within a normal
range, have still been seen to develop intracranial aneurysms
(Chauveau et al. 1994; Gieteling and Rinkel 2003; Niemczyk
et al. 2013; Xu et al. 2010). Pathogenic variants in the PKD1
and PKD2 genes are causative for ADPKD and account for
85 % and 15 % of diagnoses, respectively (Niemczyk, 2015).
Patients with pathogenic variants in PKD1 or PKD2 appear to
have an equivalent risk of IBA (Rossetti et al. 2003). PKD1
and PKD2 mutations cause defects in the mechanosensory
cilia found on renal and vascular endothelium, which leads
to cyst and aneurysm formation, respectively (AbouAlaiwi
et al. 2014, 2009; Nauli et al. 2003, 2008). Patients with tu-
berous sclerosis complex can also have a concurrent diagnosis
of ADPKD when their disease is caused by a contiguous gene
deletion affecting TSC2 and PKD1 at chromosome 16p13.3.
These patients not only have more severe kidney disease, but
are also at risk for intracranial aneurysms (Chen et al. 2002;
Longa et al. 1997; Sampson et al. 1997).
Ehlers-Danlos Syndrome
Ehlers-Danlos syndrome (EDS) is an autosomal dominant
connective tissue disorder. In classical EDS, the majority of
patients have pathogenic variants in COL5A1 and COL5A2,
while in vascular EDS, previously referred to as EDS Type IV,
variants inCOL3A1 are responsible for disease (De Paepe and
Malfait 2012). Vascular EDS patients have a high risk of mor-
tality due to vascular fragility that often leads to hemorrhage
(De Paepe and Malfait 2012). Intracranial aneurysms have
been reported in both classical and non-classical forms of
EDS, but relatively speaking it is patients with the vascular
subtype of EDS who are at the highest risk for IBA formation
(Chen et al. 2013; Kato et al. 2001; Kim et al. 2016; Lummus
et al. 2014; Mirza et al. 1979; Oderich et al. 2005; Schievink
et al. 1990, 2002). Kim et al. (2016) found intracranial aneu-
rysms in 12 individuals, seven of whom had vascular EDS,
from a chart review of 99 EDS patients (mean age 41.7 years)
who underwent brain imaging. There is currently no consen-
sus on the clinical utility of screening for intracranial
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aneurysms among otherwise asymptomatic vascular EDS pa-
tients. Results of a positive test on such screening may not be
easily actionable, because of the high risks associated with
surgical intervention. If screening is desired, a non-invasive
approach (such as MRA) should be strongly considered in
these patients, in order to avoid further weakening of the vas-
culature (North et al. 1995; Oderich et al. 2005). Certain ter-
tiary care centers with specialized expertise have reported low
rates of complications from endovascular procedures in EDS
(Lum et al. 2011a, b), such that screening may be safe for EDS
patients receiving care at experienced centers.
Loeys-Dietz Syndrome
Loeys-Dietz syndrome (LDS) is a connective tissue disorder
characterized by severe vascular defects, primarily arterial an-
eurysms, that can hemorrhage or dissect very early in life
(Loeys et al. 2005;Williams et al. 2007). Autosomal dominant
mutations in TGF-β pathway genes, most frequently TGFBR1
and TGFBR2, cause LDS. Although LDS is not commonly
listed as having an association with IBA, a number of patient
cases have reported IBA as a feature (Hughes et al. 2011;
Levitt et al. 2012; Loeys et al. 2005, 2006; Rodrigues et al.
2009; Williams et al. 2007). Cerebrovascular bleeding is the
third leading cause of death in LDS patients, and intracranial
aneurysms have been seen at a frequency ranging between 10
and 28%. (Kim et al. 2016; Loeys et al. 2006; Rodrigues et al.
2009; Vanakker et al. 2011). Although further studies are
needed to assess the clinical utility of screening LDS patients
specifically for intracranial aneurysms, surveillance of each
part of the vascular tree is currently recommended every two
years (MacCarrick et al. 2014).
Marfan Syndrome
Marfan syndrome is an autosomal dominant connective tissue
disorder caused by pathogenic variants in FBN1. It is character-
ized by skeletal, ocular, and cardiovascular malformations with
wide phenotypic variability. Aortic aneurysm, dissection, and
root enlargement are the most commonly reported vascular de-
fects (Dietz et al. 1991; Pyeritz 2016). IBA have been associated
with Marfan syndrome through multiple case reports (Finney
et al. 1976; Higashida et al. 1988; Matsuda et al. 1979; Ohtsuki
et al. 1984; Hainsworth and Mendelow, 1991; Schievink et al.
1997; Stehbens et al. 1989). Conway et al. (1999) did not find
sufficient evidence for an association between intracranial aneu-
rysms and Marfan syndrome upon autopsy of 25 patients. Only
one patient autopsied was found to have an intracranial aneu-
rysm, a number that would agree with the general population
frequency. However, a recent retrospective chart review of 59
Marfan syndrome patients estimated that 14 % have one or more
intracranial aneurysms (Kim et al. 2016). Specific screening for
intracranial aneurysms is not routinely recommended in Marfan
syndrome patients, though it could be considered in familymem-
bers affected by Marfan syndrome who also have a first-degree
relative affected by IBA, whether or not that family member also
has a diagnosis of Marfan syndrome.
Neurofibromatosis Type I
Neurofibromatosis Type I (NF1) is an autosomal dominant
condition caused by pathogenic variants in NF1. The primary
characteristics of NF1 are café-au-lait spots, iris Lisch nodules,
and benign neurofibromas (Conway et al. 2001). Vascular ab-
normalities are also a recognized characteristic of NF1 and
patients under 29 years of age have an increased prevalence
Table 3 Prevalence of intracranial aneurysms in selected syndromes and their associated gene(s)
Relative Prevalence Syndrome OMIM Number(s) Prevalence of patients
with IBA
Associated Genes
Frequent Autosomal Dominant Polycystic Kidney Disease 173,900
613,095
4–17 % PKD1, PKD2
Infrequent Vascular Ehlers-Danlos Syndrome 130,050 12%a COL3A1
Loeys-Dietz Syndrome 609,192
610,168
11–28 %a TGFBR1, TFGBR2,
SMAD3b
Marfan Syndrome 154,700 14%a FBN1
Neurofibromatosis Type I 162,200 9–11 %a NF1
Rare c Pseudoxanthoma Elasticum 264,800 - ABCC6
Hereditary Hemorrhagic Telangiectasia 187,300 ~10%d ENG
Multiple Endocrine Neoplasia Type I 131,100 - MEN1
a Prevalence estimates may be influenced by selection bias and the inclusion of both fusiform and berry aneurysms
b Pathogenic variants in TGFB2 and TGFB3 also account for <5 % of LDS cases
c Individual case reports only
dAs the prevalence of IBA in HHT patients is unknown, the prevalence of arteriovenous malformations, which can also lead to cerebral hemorrhage, has
been given
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of IBA relative to the general population risk (Rasmussen et al.
2001). Intracranial aneurysms have been documented as a ce-
rebrovascular feature of NF1 (Friedman et al. 2002; Jett and
Friedman 2010). Retrospective reviews of NFI patient data
have reported the prevalence of intracranial aneurysms to be
between 9 and 11 %. The youngest reported NF1 patient to
have an intracranial aneurysm was 1 year of age. However,
routine screening for intracranial aneurysms is not recommend-
ed for NF1 patients (Muhonen et al. 1991; Rosser et al. 2005;
Schievink et al. 2005; Uranishi et al. 1995; Zhao and Han 1998;
Zöller et al. 1995). Conway and coauthors (Conway et al. 2001)
did not detect any intracranial aneurysms in their autopsy study
of 25 NF1 patients between 3 and 69 years of age.
Other Syndromes
Multiple Endocrine Neoplasia Type I (Adachi et al. 1993),
Pseudoxanthoma Elasticum (Allison et al. 1998; Bock and
Schwegler 2008; Munyer and Margulis 1981), and
Herediatary Hemorrahagic Telangiectasia (HHT) (Willemse
et al. 2000) are often mentioned as being associated with
IBA. While all have had individual patient case reports which
document the presence of intracranial aneurysms, these data are
not as robust as are the data for the syndromes listed above and
in Table 3. Specific recommendations for IBA screening in
these disorders must await larger cohort studies, though in the
case of HHT, the currently-recommended screening protocols
to detect cerebral arteriovenous malformations (AVM) would
be expected to detect IBA as well (McDonald and Pyeritz
2000). Most frequently in HHT patients intracranial aneurysms
form along arteries leading into AVM (Willemse et al. 2000).
Patients with fibromuscular dysplasia (FMD) are also believed
to be at risk for aneurysms in the brain and elsewhere, so current
recommendations are that all FMD patients have cross-
sectional imaging from head to pelvis with a sensitive method
like CTA or MRA (Kadian-Dodov et al. 2016). Though auto-
somal dominant inheritance has been suggested for
fibromuscular dysplasia, definitive genetic candidates have
yet to emerge (Kiando et al. 2015). Moyamoya angiopathy,
which is also associated with NF1 (Koss et al. 2013), appears
to have a pathogenesis that is distinct from that of intracranial
berry aneurysms; it is not clear whether the occasional associ-
ation of intracranial aneurysms with moyamoya (Kawaguchi
et al. 1996; Yu et al. 2016) reflects a common pathophysiology
at the molecular level, or whether it reflects pathology at one
vascular site that perturbs downstream hemodynamics.
Special Counseling Situations
Certified genetic counselors will already be thoroughly famil-
iar with family trees that suggest Mendelian inheritance that
follows autosomal dominant, autosomal recessive or X-linked
patterns of inheritance. Even if a DNA-level diagnosis is not
available in those situations, counselors will be able to esti-
mate recurrence risks and suggest appropriate follow-up.
Where feasible, risk for apparently-unaffected family mem-
bers may be refined by imaging studies in their living parents
or grandparents. Unusual situations may arise that demand
consideration of screening protocols that have not been vali-
dated by prospective studies. We are aware of at least two
independent families in which a child under age 15 suffered
a subarachnoid haemorrhage attributed to a berry aneurysm of
the cerebral circulation (Fig. 1c and unpublished data).
Though neither of these children are known to have another
affected first-degree relative, it must be borne in mind that rare
children who develop diseases that are otherwise considered
common among elderly adults may well have an underlying
high-penetrance risk allele. Challenging situations such as
these may demand a multidisciplinary approach that includes
engagement of the genetic counselor with other medical and
surgical practitioners involved in the family’s care.
Counselors may also need to provide an opinion to insurance
providers as to the utility of screening in one family member
for the purposes of estimating risk in other family members. In
the examples given above, screening of clinically-unaffected
sibs may be worthwhile, but screening of clinically-unaffected
parents may also provide useful information. Were one or
more aneurysms detected in a parent, the unaffected sibs
would definitely be considered to be at risk and to merit
screening under current guidelines.
Conclusions
Here we have reviewed and summarized the genetic in-
vestigations conducted in sporadic and familial intracranial
berry aneurysm populations to date. While several loci and
candidate genes have been identified, a conclusive gene-
disease association has not yet been made for non-
syndromic families. Further next-generation sequencing
studies are needed to identify a causative gene in families
with intracranial aneurysms as the only clinical finding.
Patients with FIA are at increased risk for aneurysm for-
mation and rupture compared to the general population,
and screening of all first-degree relatives using MRA or
CTA is recommended. Definitive identification of a single-
gene cause of FIA in a particular family or group of
families would allow genetic confirmation as to which
family members are at risk. Family members who did
not inherit the pathogenic variant would not need to un-
dergo regular screening, and could obtain peace of mind
regarding aneurysm formation later in life. As there is not
yet a genetic test, or a conclusive familial recurrence rate,
genetic counselors will need to estimate patient risk for
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developing IBA on a case-by-case basis, through analyz-
ing inheritance within a pedigree. Counselors should also
investigate the possibility of an associated syndrome by
taking a targeted family history; if warranted by specific
findings, they could then refer the patient to a medical
geneticist or other suitable specialist.
We have also discussed a number of Mendelian syn-
dromes, primarily hereditary connective tissue disorders,
which confer increased risk for IBA development. Of
these syndromes, ADPKD has the strongest documented
association with IBA. The prevalence estimates of intra-
cranial aneurysms in Marfan syndrome, NF1, EDS, and
LDS are likely biased to report a higher percentage of
affected patients. In the studies discussed, patients identi-
fied as being at risk for vascular complications received
brain imaging, whereas patients lacking these risk factors
did not receive screening and were not included in the
prevalence calculation. Additionally, many of these studies
also include fusiform aneurysms when documenting the
presence of intracranial aneurysms. These two methodo-
logical limitations have prevented an accurate measure-
ment of IBA prevalence in the syndromes listed above,
which may or may not be significantly higher than the
background population risk. LDS prevalence measurements
may not be as affected by these limitations if patients are
receiving screening every two years as recommended. It is
possible that, as more data is collected on the natural
history of this syndrome, LDS will move to a higher risk
category for IBA. The heterogeneity of findings on IBA
within Marfan syndrome, NF1, EDS, and LDS does not
give clear direction to genetic counselors. However, genet-
ic counselors should be aware that patients with these
syndromes could be at increased risk for IBA develop-
ment, and may want to recommend screening for patients
who present with additional risk factors such as a specific
history of IBA in their family members.
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